FDA’s MoCRA implementation outlines facility registration, product listing, adverse event reporting, and safety substantiation requirements relevant to Med Spa retail skincare and private-label cosmetic product models.
FDA Highlights MoCRA Requirements for Cosmetic Facilities and Product Listings
On February 11, 2026, the FDA announced updates to Cosmetics Direct and related materials to help cosmetic facilities prepare for biennial registration renewal under the Modernization of Cosmetics Regulation Act of 2022. The update applies to cosmetic product facilities required to register with the FDA and sits within the agency’s broader MoCRA implementation work, including facility registration, product listing, serious adverse-event reporting, and safety substantiation requirements. For Med Spa retail skincare and private-label cosmetic product models, the update adds federal cosmetics context on product chain roles, responsible person duties, and manufacturers’ or processors’ roles in facility registration.
MoCRA Implementation Includes Registration, Listing, and Reporting Tools
The February 2026 Cosmetics Constituent Update focuses on the FDA’s updates to Cosmetics Direct and related materials for cosmetic facilities preparing for biennial registration renewal. In a separate FDA Voices article, current as of May 4, 2026, Steven Kozlowski, M.D., FDA’s Chief Scientist, described facility registration and product listing as part of the agency’s broader implementation of the Modernization of Cosmetics Regulation Act of 2022.
Under MoCRA, cosmetic product manufacturers and processors are subject to facility registration requirements, while responsible persons must list marketed cosmetic products, including product ingredients, with the FDA. FDA’s February 2026 Cosmetics Constituent Update also identifies Cosmetics Direct as an electronic submissions portal used for cosmetic product facility registration and product listing. MoCRA also added requirements and authorities related to safety substantiation, serious adverse-event reporting, records access, and mandatory recalls.
The FDA reported that it now has more than 15,000 active cosmetic product facility registrations and more than 1 million active cosmetic product listings. According to the agency, facility registration helps identify who is manufacturing or processing cosmetic products and where, while product listing provides information about marketed cosmetic products and their ingredients.
For Med Spa and dermatology-adjacent aesthetic practices, the connection is most direct when retail skincare or private-label cosmetic products are sold alongside treatments such as facials, lasers, microneedling, chemical peels, injectables, acne care, or skin-rejuvenation services. These product lines may involve manufacturers, processors, distributors, label owners, or responsible persons with MoCRA obligations, while facility registration depends on whether a facility manufactures or processes cosmetic products.
Source Attribution
According to the FDA’s February 11, 2026, Cosmetics Constituent Update, the agency announced updates to Cosmetics Direct, its user guide, and related materials to assist cosmetic facilities preparing for biennial registration renewal under MoCRA. A separate FDA Voices article by Steven Kozlowski, M.D., Chief Scientist at FDA, described MoCRA as an expansion of the agency’s cosmetics authority, including facility registration requirements for cosmetic product manufacturers and processors and product listing requirements for responsible persons.
Compliance Context for Cosmetic Product Oversight in Med Spa and Aesthetic Practices
MoCRA expanded FDA authority over cosmetics by adding federal requirements for facility registration, product listing, serious adverse-event reporting, product safety substantiation, records access, and mandatory recall authority. The FDA defines cosmetics as products intended to be applied to the body for cleansing, beautifying, promoting attractiveness, or altering appearance, excluding soap.
The FDA Voices article states that cosmetic product manufacturers and processors are subject to facility registration requirements, while responsible persons must list marketed cosmetic products and ingredients with the FDA. Additionally, the FDA’s Registration & Listing of Cosmetic Product Facilities and Products page identifies exemptions for certain small businesses and for certain products or facilities subject to drug or device requirements.
In Med Spa and dermatology-adjacent aesthetic settings, MoCRA may be relevant to cosmetic products sold as part of the business model, including retail skincare, post-procedure skincare, cosmetic acne-care products, skin-rejuvenation products, cosmetic sun-care products, or private-label cosmetic lines.
Private-label or branded cosmetic product models may be relevant to MoCRA when the practice’s name appears on the product label, products are marketed under the practice’s brand, or the practice is involved in distribution, labeling, or product listing. Facility registration is tied to manufacturing or processing cosmetic products, while product listing and responsible-person duties are tied to the marketed cosmetic product and the party identified for that product.
Separate FDA activity involving telehealth GLP-1 marketing practices, as well as state-level enforcement involving unlicensed cosmetic injections, provides a Med Spa context for product oversight, safety concerns, advertising representations, adverse events, and scope-of-practice concerns.
Practical Implications for Med Spa Operators
Based on the MoCRA requirements described by the FDA, key compliance considerations for Med Spa operators with retail skincare or private-label cosmetic products include:
- Inventory all cosmetic products sold through the practice, including professional skincare, post-procedure products, skin-rejuvenation products, and private-label lines.
- Confirm which manufacturer, processor, distributor, label owner, or responsible person is connected to each cosmetic product sold or marketed through the practice.
- Verify that private-label cosmetic products have clear documentation for product listing, ingredient information, labeling, and responsible-person duties.
- Identify how cosmetic product complaints and adverse reactions are directed to the manufacturer, distributor, label owner, or responsible person identified for the product.
- Maintain supplier and product documentation showing which party manufactures, processes, distributes, labels, or lists each cosmetic product sold through the practice.
What to Watch Next
The FDA Voices article states that the FDA will continue providing information on MoCRA implementation, cosmetic product safety, ingredient information, recalls, and testing results. Future FDA materials on biennial facility registration renewal, product listing updates, adverse-event reporting, records access guidance, and cosmetic good manufacturing practice requirements may provide additional context for Med Spa and dermatology-adjacent practices with retail or private-label cosmetic product lines.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “Connecticut State Capitol in Hartford” by EGryk, via Wikimedia Commons, licensed under CC BY-SA 4.0.
